CEQUA™ demonstrated safety and tolerability in clinical trials1-3,a
Most adverse events were mild2
- The most common adverse events reported in >5% of patients were instillation site pain (22%) and conjunctival hyperemia (6%)1,b
- Most ocular adverse events reported by patients treated with CEQUA were mild (80%) or moderate (17%)2
- Discontinuation rate due to ocular adverse events was 3.2% for CEQUA vs 1.1% for vehicle2
Read the published journal articles that evaluated the safety and efficacy of CEQUA:
Most patients in a clinical trial found CEQUA to be comfortable3
Additional safety information
Incidence of blurred vision was <1%2
No reported taste alterations2
In healthy adults, ocular administration of CEQUA led to negligible systemic exposure to cyclosporine2
Indications and Usage
CEQUA™ (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Important Safety Information
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.
Adverse Reactions
The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.
Please see the Full Prescribing Information.
- The safety of CEQUA was evaluated in clinical trials that included 769 patients who received at least 1 dose of study treatment.1
- Instillation site pain includes burning and stinging.2